Australian Opera2Parliament charity ride has unexpected origin

The Opera2Parliament bicycle charity ride, which benefits Lymphoma Australia, just wrapped up its second annual ride, a bike ride from Sydney to Canberra's Parliament House, and this year alone raised about $50,000 for the fight against lymphoma. But were it not for a fluke discovery last year, the charity ride may never have come about.

It began last year, when 25-year-old Jovan Pejic, his brother Nikola, and a friend decided to bicycle from Sydney to Canberra for no better reason than the challenge.

In the lead-up to their ride, Pejic noticed a lump in his groin. He ignored it until he could ignore it no longer. Three days before their ride was to commence, he got word from his doctor than he had follicular lymphoma, an indolent non-Hodgkin's lymphoma and one of the most frequently diagnosed NHLs. His firs tthoughts were to cancel the bike ride.

Nikola Pejic thought they should instead try to turn it into something to benefit people with lymphoma, and suddenly, a new charity bike ride was born.

Pejic himself, an elite judo athlete, recently finished radiation treatments. Prior to his diagnosis he was in outstanding shape, which he says is why he ignored the lump.

Source: Canberra Times

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap